Page 29 - Read Online

Fujimoto et al. J Cancer Metastasis Treat 2021;7:66 https://dx.doi.org/10.20517/2394-4722.2021.157 Page 11 of 14

Conflicts of Interest
Fujimoto A declared that there are no conflicts of interest. Suzuki R received honoraria from Bristol-Myers
Squibb, Novartis, Kyowa Hakko Kirin, Chugai Pharmaceuticals, Takeda, Meiji Seika Pharma, MSD, Otsuka,
Celgene, Eisai Pharmaceuticals, Abbvie Inc., and Janssen outside the submitted work.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Campo E, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO
Press; 2008.
2. Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in Japan:
incidence of recently recognized entities. Pathol Int 2000;50:696-702. DOI
3. Bassig BA, Au WY, Mang O, et al. Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United
States, 2001-2010. Cancer Epidemiol 2016;42:15-23. DOI PubMed
4. Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health
Organization classification. Am J Clin Pathol 2012;138:429-34. DOI PubMed
5. Suzuki R, Suzumiya J, Yamaguchi M, et al; NK-cell Tumor Study Group. Prognostic factors for mature natural killer (NK) cell
neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-40. DOI
6. Au WY, Weisenburger DD, Intragumtornchai T, et al; International Peripheral T-Cell Lymphoma Project. Clinical differences between
nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
Blood 2009;113:3931-7. DOI PubMed
7. Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma
diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 2017;35:32-9. DOI PubMed
8. Fox CP, Civallero M, Ko Y, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort
study from the international T-cell Project. Lancet Haematol 2020;7:e284-94. DOI PubMed
9. Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell
and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol 2012;36:481-99. DOI
PubMed
10. Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.
Blood 1986;67:925-30. PubMed
11. Suzuki R, Suzumiya J, Nakamura S, et al; NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large
granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004;18:763-70. DOI PubMed
12. Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic
hematopoietic stem cell transplantation. Cancer Sci 2012;103:1079-83. DOI PubMed PMC
13. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts:
prospective analysis of 108 cases. Blood 2012;119:673-86. DOI PubMed
14. Ko YH, Park S, Kim K, Kim SJ, Kim WS. Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a
favorable prognosis? Acta Haematol 2008;120:199-206. DOI PubMed
15. Nicolae A, Ganapathi KA, Pham TH, et al. EBV-negative aggressive NK-cell leukemia/lymphoma: clinical, pathologic, and genetic
features. Am J Surg Pathol 2017;41:67-74. DOI PubMed PMC
16. Suzuki R. NK/T Cell Lymphoma: updates in therapy. Curr Hematol Malig Rep 2018;13:7-12. DOI PubMed
17. Yang Y, Wang Y, Liu X, et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell
lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia 2021;35:1671-82. DOI PubMed PMC
18. Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a
multicentre, retrospective analysis. Lancet Oncol 2016;17:389-400. DOI PubMed
19. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective
multicenter study. J Clin Oncol 2006;24:612-8. DOI PubMed
20. Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extranasal NK/T-cell lymphoma. Blood 2009;113:6260-1; author
reply 6261-2. DOI PubMed
21. Tang YT, Wang D, Luo H, et al. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood
Cancer J 2017;7:660. DOI PubMed PMC